Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 5/20 | 0.89 |
| ▸ | MEN1 | O00255 | 1/20 | 0.59 |
| ▸ | HRH1 | P35367 | 1/20 | 0.55 |
| ▸ | STAT3 | P40763 | 6/20 | 0.52 |
| ▸ | HTT | P42858 | 3/20 | 0.52 |
| ▸ | MAPT | P10636 | 2/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.52 |
| ▸ | NPC1 | O15118 | 1/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.52 |
| ▸ | NR2F2 | P24468 | 3/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | DRD2 | P14416 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4922800 | 0.94 | HTR2C (1.00) | HTR2CMEN1HRH1STAT3HTT | |
| Hydrochloric Acid SCHEMBL30569569 | 0.93 | HTR2C (0.97) | HTR2CMEN1HRH1STAT3HTT | |
| SCHEMBL13640916 | 0.85 | HTR2C (0.72) | HTR2CMEN1HRH1STAT3HTT | |
| SCHEMBL12789897 | 0.79 | MEN1 (0.64) | HTR2CMEN1HRH1STAT3HTT | |
| SCHEMBL12789895 | 0.78 | MEN1 (0.71) | HTR2CMEN1HRH1STAT3HTT | |
| SCHEMBL5107750 | 0.78 | HTR2C (0.70) | HTR2CMEN1HRH1STAT3HTT | |
| SCHEMBL12789889 | 0.74 | MEN1 (0.70) | HTR2CMEN1HRH1STAT3HTT | |
| SCHEMBL12789913 | 0.74 | MEN1 (1.00) | HTR2CMEN1HRH1STAT3HTT | |
| SCHEMBL4192433 | 0.74 | HTR2C (0.65) | HTR2CMEN1HRH1STAT3HTT | |
| SCHEMBL4245389 | 0.74 | HTR2C (0.65) | HTR2CMEN1HRH1STAT3HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160045504-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF LEUKEMIA | THE REGENTS OF THE UNIVERSITY OF MICHIGAN | 2016-02-18 | — | — | US | disclosed |
| US-20070043095-A1 | Derivatives of 2-arylimino-2,3-dihydrothiazoles, their preparation processes and their therapeutic use | IPSEN PHARMA S.A.S. (FR) | 2007-02-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070043095-A1 | Derivatives of 2-arylimino-2,3-dihydrothiazoles, their preparation processes and their therapeutic use | SSTR2, SSTR5, SSTR3 | HTR2C 60/4885MEN1 893/4885HRH1 152/4885 |
| US-20160045504-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF LEUKEMIA | MLLT1, MCL1, MLLT3 | HTR2C 4728/4885MEN1 10/4885HRH1 3264/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.